12:00 AM
Jul 02, 2012
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Kyowa Hakko Kirin, Otsuka Pharmaceutical sales and marketing update

Otsuka granted Kyowa exclusive rights to market diabetes drug saxagliptin in Japan. Otsuka will receive ¥3 billion ($37.5 million) up front and is eligible for ¥8.2 billion ($102.5 million) upon Japanese regulatory approval, plus royalties. An NDA for the oral dipeptidyl peptidase-4 (DPP-4) inhibitor to treat Type II diabetes is under review...

Read the full 247 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >